Pivotal bioVenture Partners Investment Advisor LLC
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$251.8M2026 Q3
Positions14
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.91.1%
Top Holdings
PCVX
Vaxcyte
32.2%
ARQT
Arcutis Biotherapeutics
10.6%
TRVI
Trevi Therapeutics
9.9%
AVLN
Avalyn Pharma
9.8%
EVMN
Evommune
6.3%
IMNM
Immunome
6.3%
OCS
Oculis
6.2%
OBX
Obsidian Therapeutics
4.7%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.